 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU has entered an agreement with Eurofins CDMO contract development and manufacturing organization Alphora Inc for the manufacturing of its LSD derivative molecule, TD-0148A, the company announced Wednesday. TD-0148A is a second-generation lysergic acid diethylamide LSD derivative molecule, 2-bromo-LSD, that BetterLife believes will mimic the projected therapeutic potential of LSD, without causing its undesirable psychoactive dissociative side effects, such as hallucinations. 